CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Geny PiroCarmine CarboneAntonio AgostiniAnnachiara EspositoMaria De PizzolRubina NovelliMarcello AllegrettiAndrea AraminiAlessia CaggianoAlessia GranittoFrancesco De SanctisStefano UgelVincenzo CorboMaurizio MartiniRita Teresa LawlorAldo ScarpaGiampaolo TortoraPublished in: British journal of cancer (2022)
Ladarixin in combination with anti-PD-1 might represent an extremely effective approach for the treatment of immunotherapy refractory PDAC, allowing pro-tumoral to immune-permissive microenvironment conversion.